Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325866 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
A Phase 1 study of Solid Tumors, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT05325866: Completed Phase 1 study of Solid Tumors, sponsored by Amgen.
NCT05325866 is a Phase 1 study of Solid Tumors that has completed, run by Amgen. The registered enrollment target is 260 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05325866, a Phase 1 study of Solid Tumors, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Conditions Studied
Interventions
- DRUG Bemarituzumab
Study Locations (20)
Texas
- Texas Oncology - Dallas Fort Worth - Dallas
- University of Texas MD Anderson Cancer Center - Houston
- US Oncology Research Investigational Products Center - Irving
- Texas Oncology Northeast Texas - Tyler
Buenos Aires
- Instituto Alexander Fleming - Capital Federal
- Hospital Aleman - Ciudad Autonoma de Buenos Aires
- Fundacion Cenit Para La Investigacion - Ciudad Autonoma de Buenos Aires
- Hospital Italiano de La Plata - La Plata
New South Wales
- Liverpool Hospital - Liverpool
- Prince of Wales Hospital - Randwick
- Wollongong Hospital - Wollongong
California
- City of Hope National Medical Center - Duarte
- University of California Irvine - Orange
Colorado
- Rocky Mountain Cancer Centers - Aurora
Indiana
- Community Health Network MD Anderson Cancer Center - North - Indianapolis
Michigan
- Henry Ford Hospital - Detroit
Tennessee
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 1 |
What the finished NCT05325866 record still lists
NCT05325866 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Bemarituzumab is the first listed.
NCT05325866 names 20 study sites across 11 states, led by Texas, Buenos Aires, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05325866 about?
NCT05325866 is a clinical study titled "A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression". The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
What is the current status of trial NCT05325866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2022-09-23. Estimated completion is 2026-01-28.
What conditions does trial NCT05325866 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT05325866?
The interventions under investigation include: Bemarituzumab (DRUG).
Who is sponsoring clinical trial NCT05325866?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05325866 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05325866's enrollment target sits among peer trials
260 22nd of 125 higher than 104 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI